Vimarsana
Biggest News Aggregation in the World

Page 3 - Safety Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safety Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safety Study Today - Breaking & Trending Today

FASENRA approved for treatment of children aged 6 to 11 with severe asthma - Vimarsana News

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Additional indication for pediatric patients with severe eosinophilic asthma ...

Psychological Safety in Today's Global Workforce - Vimarsana News

Psychological Safety in Today's Global Workforce

Workplace Options (WPO) Debuts Data-Driven Study Across 9 Nations; Explores Workplace Issues, Need for Inclusive Leadership, and Renewed Commitment...

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - Vimarsana News

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

Psychological Safety in Today's Global Workforce - Vimarsana News

Psychological Safety in Today's Global Workforce

Workplace Options presents first global study on how psychological safety affects employees in nine nations utilizing data from WPO clinicians-no surveys....

FDA Approves Vadadustat for Oral Treatment of Anemia Due to Chronic Kidney Disease - Vimarsana News

FDA Approves Vadadustat for Oral Treatment of Anemia Due to Chronic Kidney Disease

Vadadustat (Vafseo; Akebia Therapeutics Inc) is indicated for individuals with chronic kidney disease who have been receiving dialysis for at least 3 months.